Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 8, 2008, Pages 1501-1509

  Hasselblom, Sverker ^a   Ridell, Börje ^a   Sigurdardottir, Margret ^a   Hansson, Ulrika ^a   Nilsson Ehle, Herman ^a   Andersson, Per Ola ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

bcl 2; Cell cycle and apoptosis changes; Cyclin A; DLBCL; Galectin 3; GCB; Ki 67; Lymphoma and Hodgkin disease; Neoplasia; Prognostication

Indexed keywords

BLEOMYCIN; CYCLIN A; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GALECTIN 3; KI 67 ANTIGEN; MITOXANTRONE; PREDNISONE; PROTEIN BCL 2; VINCRISTINE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL CYCLE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 51349161389     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802140055     Document Type: Article

References (43)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 329, pp. 987-994.
2. Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S. Rosenwald, A. et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, pp. 503-511.
3. Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E. Fisher, R. I. et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 1937-1947.
4. Hans, C. P., Weisenburger, D. D., Greiner, T. C., Gascoyne, R. D., Delabie, J. Ott, G. et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, pp. 275-282.
5. Berglund, M., Thunberg, U., Amini, R. M., Book, M., Roos, G. Erlanson, M. et al. (2005) Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol, 18, pp. 1113-1120.
6. Muris, J. J., Meijer, C. J., Vos, W., van Krieken, J. H., Jiwa, N. M. Ossenkoppele, G. J. et al. (2006) Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 208, pp. 714-723.
7. De Paepe, P., Achten, R., Verhoef, G., Wlodarska, I., Stul, M. Vanhentenrijk, V. et al. (2005) Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol, 23, pp. 7060-7068.
8. Bai, M., Agnantis, N. J., Skyrlas, A., Tsanou, E., Kamina, S. Galani, V. et al. (2003) Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol, 16, pp. 471-480.
9. Bai, M., Skyrlas, A., Agnantis, N. J., Kamina, S., Kitsoulis, P. and Kanavaros, P. (2004) Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes. Anticancer Res, 24, pp. 3081-3088.
10. Bai, M., Skyrlas, A., Agnantis, N. J., Kamina, S., Tsanou, E. Grepi, C. et al. (2004) Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Mod Pathol, 17, pp. 847-856.
11. Hill, M. E., MacLennan, K. A., Cunningham, D. C., Vaughan Hudson, B, Burke, M. Clarke, P. et al. (1996) Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study. Blood, 88, pp. 1046-1051.
12. Hermine, O., Haioun, C., Lepage, E., d'Agay, M. F., Briere, J. Lavignac, C. et al. (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood, 87, pp. 265-272.
13. Gascoyne, R. D., Adomat, S. A., Krajewski, S., Krajewska, M., Horsman, D. E. Tolcher, A. W. et al. (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood, 90, pp. 244-251.
14. Barrans, S. L., Carter, I., Owen, R. G., Davies, F. E., Patmore, R. D. Haynes, A. P. et al. (2002) Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood, 99, pp. 1136-1143.
15. Colomo, L., Lopez-Guillermo, A., Perales, M., Rives, S., Martinez, A. Bosch, F. et al. (2003) Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 101, pp. 78-84.
16. Jerkeman, M., Anderson, H., Dictor, M., Kvaloy, S., Akerman, M. and Cavallin-Stahl, E. (2004) Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study. Ann Hematol, 83, pp. 414-419.
17. Sanchez, E., Chacon, I., Plaza, M. M., Munoz, E., Cruz, M. A. Martinez, B. et al. (1998) Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol, 16, pp. 1931-1939.
18. Iqbal, J., Neppalli, V. T., Wright, G., Dave, B. J., Horsman, D. E. Rosenwald, A. et al. (2006) BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol, 24, pp. 961-968.
19. Gerdes, J., Schwab, U., Lemke, H. and Stein, H. (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer, 31, pp. 13-20.
20. Bullwinkel, J., Baron-Luhr, B., Ludemann, A., Wohlenberg, C., Gerdes, J. and Scholzen, T. (2006) Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol, 206, pp. 624-635.
21. Gerdes, J., Stein, H., Pileri, S., Rivano, M. T., Gobbi, M. Ralfkiaer, E. et al. (1987) Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet, 2, pp. 448-449.
22. Grogan, T. M., Lippman, S. M., Spier, C. M., Slymen, D. J., Rybski, J. A. Rangel, C. S. et al. (1988) Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood, 71, pp. 1157-1160.
23. Miller, T. P., Grogan, T. M., Dahlberg, S., Spier, C. M., Braziel, R. M. Banks, P. M. et al. (1994) Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood, 83, pp. 1460-1466.
24. Hans, C. P., Weisenburger, D. D., Greiner, T. C., Chan, W. C., Aoun, P. Cochran, G. T. et al. (2005) Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol, 18, pp. 1377-1384.
25. Nakamine, H., Bagin, R. G., Vose, J. M., Bast, M. A., Bierman, P. J. Armitage, J. O. et al. (1993) Prognostic significance of clinical and pathologic features in diffuse large B-cell lymphoma. Cancer, 71, pp. 3130-3137.
26. Kossakowska, A. E., Huchcroft, S., Boras, V. and Urbanski, S. J. (1991) Prognostic significance of proliferative activity of diffuse large cell lymphomas. Hematol Pathol, 5, pp. 101-107.
27. Tzankov, A., Gschwendtner, A., Augustin, F., Fiegl, M., Obermann, E. C. Dirnhofer, S. et al. (2006) Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clin Cancer Res, 12, pp. 2125-2132.
28. Obermann, E. C., Went, P., Pehrs, A. C., Tzankov, A., Wild, P. J. Pileri, S. et al. (2005) Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Oncol Rep, 14, pp. 1461-1467.
29. Filipits, M., Jaeger, U., Pohl, G., Stranzl, T., Simonitsch, I. Kaider, A. et al. (2002) Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res, 8, pp. 729-733.
30. Hasselblom, S., Ridell, B., Nilsson-Ehle, H. and Andersson, P. O. (2007) The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma - a population-based study. Leuk Lymphoma, 48, pp. 736-745.
31. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. Connors, J. M. et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
32. Hoyer, K. K., Pang, M., Gui, D., Shintaku, I. P., Kuwabara, I. Liu, F. T. et al. (2004) An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol, 164, pp. 893-902.
33. Schemper, M. and Smith, T. L. (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials, 17, pp. 343-346.
34. Gerdes, J., Dallenbach, F., Lennert, K., Lemke, H. and Stein, H. (1984) Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol, 2, pp. 365-371.
35. Slymen, D. J., Miller, T. P., Lippman, S. M., Spier, C. M., Kerrigan, D. P. Rybski, J. A. et al. (1990) Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol, 8, pp. 986-993.
36. Leoncini, L., Del Vecchio, M T, Megha, T., Barbini, P., Galieni, P. Pileri, S. et al. (1993) Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol, 142, pp. 755-763.
37. Wilson, W. H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S. M. Jaffe, E. S. et al. (1997) Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood, 89, pp. 601-609.
38. Vairo, G., Innes, K. M. and Adams, J. M. (1996) Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene, 13, pp. 1511-1519.
39. Greider, C., Chattopadhyay, A., Parkhurst, C. and Yang, E. (2002) BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Oncogene, 21, pp. 7765-7775.
40. Shaffer, A. L., Yu, X., He, Y., Boldrick, J., Chan, E. P. and Staudt, L. M. (2000) BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity, 13, pp. 199-212.
41. Mounier, N., Briere, J., Gisselbrecht, C., Emile, J. F., Lederlin, P. Sebban, C. et al. (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood, 101, pp. 4279-4284.
42. Wilson, K. S., Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C. A. Gill, K. K. et al. (2007) CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma, 48, pp. 1102-1109.
43. Nyman, H., Adde, M., Karjalainen-Lindsberg, M. L., Taskinen, M., Berglund, M. Amini, R. M. et al. (2007) Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood, 109, pp. 4930-4935.